Related Experiment Video
Updated: Mar 7, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
Onset of Microscopic Polyangiitis in Binephrectomied Patient on Chronic Hemodialysis-Case Report
Aleksandar Jankovic1, Vesna Maslarevic-Radovic1, Petar Djuric1
1Clinical Department for Nephrology with Dialysis, University Medical Center Zvezdara , Belgrade , Serbia.
Introduction:
Microscopic polyangiitis (MPA) is one of the causes of the pulmonary-renal syndrome associated with elevated non-specific markers of inflammation and antineutrophil cytoplasmic autoantibody (ANCA) positivity in 50-75%. De novo occurrence of the disease in patients on chronic hemodialysis (HD) has not been described.
Case Presentation:
We presented patient who developed MPO-ANCA-associated MPA with lung and musculoskeletal involvement after 4 years on regular HD due to bilateral nephrectomy. After excluding the other causes of MPO-ANCA positivity, diagnosis was confirmed even without renal biopsy. Patient received standard immunosuppression therapy and he is still in remission after 27 months.
Conclusion:
The onset of immune-mediated disease could be observed even after introduction of renal replacement therapy, which may be a diagnostic problem. Early recognition and traditional immunosuppressive regiment may provide successful outcome.
Insights
Microscopic polyangiitis (MPA) can develop in patients undergoing chronic hemodialysis (HD). Early diagnosis and standard immunosuppression led to sustained remission in a patient with newly diagnosed MPA after 4 years on HD.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Microscopic polyangiitis (MPA) is a pulmonary-renal syndrome often linked to ANCA positivity.
- De novo MPA development in patients on chronic hemodialysis (HD) is rare and previously undescribed.
- MPA diagnosis typically involves ANCA positivity (50-75%) and inflammation markers.
Purpose of the Study:
- To report a novel case of de novo microscopic polyangiitis in a patient on chronic hemodialysis.
- To highlight the diagnostic challenges and successful management of MPA in this specific patient population.
- To emphasize the possibility of immune-mediated disease onset even after initiating renal replacement therapy.
Main Methods:
- Case report of a patient on chronic HD who developed MPO-ANCA-associated MPA.
- Diagnosis confirmed through clinical presentation (lung and musculoskeletal involvement) and MPO-ANCA positivity, without renal biopsy.
- Patient managed with standard immunosuppression therapy.
Main Results:
- The patient developed MPO-ANCA-associated MPA after 4 years of regular HD.
- Diagnosis was established by excluding other causes of MPO-ANCA positivity.
- The patient achieved and maintained remission for 27 months following immunosuppressive treatment.
Conclusions:
- Immune-mediated diseases like MPA can manifest after the initiation of renal replacement therapy.
- The onset of MPA in HD patients presents diagnostic challenges.
- Early diagnosis and conventional immunosuppressive therapy are effective for achieving remission in MPA.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis II: Procedure and Complications
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Hemodialysis I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

